A6475
El texto subrayado se agregaría a la ley vigente. El texto tachado se eliminaría.
Skip to main content
Go to top ] is old law to be omitted.
LBD07098-01-5
A. 6475 2
1 selor. Such coverage shall also be provided after the patient's initial
2 diagnosis. Patients need to know if they carry the genetic or inheri-
3 tance mutation, which can help to determine possible treatments. Genetic
4 screening shall be covered for prostate and ovarian cancer patients'
5 family members. The genetic result shall not be used against family
6 members that carry the genetic or inheritance mutation for insurance
7 coverage purposes.
8 (ii) All costs associated with such additional full coverage shall not
9 be subject to annual deductibles and coinsurance but shall be borne
10 solely by the insurer.
11 § 4. Subsection (z-1) of section 4303 of the insurance law is amended
12 by adding a new paragraph 3 to read as follows:
13 (3)(A) Such policy shall provide additional full coverage for compre-
14 hensive genetic testing and FDA approved testing based on family or
15 person's history for prostatic and ovarian cancer when recommended by a
16 doctor, a board-certified geneticist or a board-certified genetic coun-
17 selor.
18 (B) All costs associated with such additional full coverage shall not
19 be subject to annual deductibles and coinsurance but shall be borne
20 solely by the insurer. Such coverage shall also be provided after the
21 patient's initial diagnosis. Patients need to know if they carry the
22 genetic or inheritance mutation, which can help to determine possible
23 treatments. Genetic screening shall be covered for prostate and ovarian
24 cancer patients' family members. The genetic result shall not be used
25 against family members that carry the genetic or inheritance mutation
26 for insurance coverage purposes.
27 § 5. This act shall take effect on the sixtieth day after it shall
28 have become a law and shall apply to all policies, contracts and certif-
29 icates issued, renewed, modified, altered or amended on or after such
30 date.
Go to top
<link href="/styles/noscript_styles.css" rel="stylesheet"/>
Sitemap
Request Information
Directions and Maps
New York State Assembly
Speaker Carl E. Heastie
- Assembly Members
- Legislative Info
- Public Hearings
- Speaker's Press
- Assembly Reports
- Committees & More
- Bill Search Home
- Laws
- Legislative Calendar
- Public Hearing Schedule
- Assembly Calendars
- Assembly Committee Agenda
- Summary
- Actions
- Committee Votes
- Floor Votes
- Memo
- Text
- LFIN
- Chamber Video/Transcript
A06475 Summary:
| BILL NO | A06475 |
| SAME AS | No Same As |
| SPONSOR | Septimo |
| COSPNSR | |
| MLTSPNSR | |
| Amd ??3216, 3221 & 4303, Ins L | |
| Requires health insurance policies to cover comprehensive genetic screening and FDA approved biomarker testing for ovarian and prostate cancers. |
A06475 Text:
STATE OF NEW YORK ________________________________________________________________________ 6475 2025-2026 Regular Sessions IN ASSEMBLY March 5, 2025 ___________ Introduced by M. of A. SEPTIMO -- read once and referred to the Commit- tee on Insurance AN ACT to amend the insurance law, in relation to requiring health insurance policies to fully cover comprehensive genetic testing and FDA approved biomarker testing for ovarian and prostate cancers The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. This act shall be known and may be cited as the "Ana Lucia 2 act". 3 § 2. Paragraph 11-a of subsection (i) of section 3216 of the insurance 4 law is amended by adding a new subparagraph (C) to read as follows: 5 (C) (i) Such policy shall provide additional full coverage for compre- 6 hensive genetic testing and FDA approved testing based on family or 7 person's history for prostatic and ovarian cancer when recommended by a 8 doctor, a board-certified geneticist or a board-certified genetic coun- 9 selor. Such coverage shall also be provided after the patient's initial 10 diagnosis. Patients need to know if they carry the genetic or inheri- 11 tance mutation, which can help to determine possible treatments. Genetic 12 screening shall be covered for prostate and ovarian cancer patients' 13 family members. The genetic result shall not be used against family 14 members that carry the genetic or inheritance mutation for insurance 15 coverage purposes. 16 (ii) All costs associated with such additional full coverage shall not 17 be subject to annual deductibles and coinsurance but shall be borne 18 solely by the insurer. 19 § 3. Paragraph 11-a of subsection (l) of section 3221 of the insurance 20 law is amended by adding a new subparagraph (C) to read as follows: 21 (C)(i) Such policy shall provide additional full coverage for compre- 22 hensive genetic testing and FDA approved testing based on family or 23 person's history for prostatic and ovarian cancer when recommended by a 24 doctor, a board-certified geneticist or a board-certified genetic coun- EXPLANATION--Matter in italics (underscored) is new; matter in brackets [Texto oficial de la Legislatura de New York. El formato se adaptó para leerlo en Ratifi.